BEAM vs RJF · rev $32.2M vs rev $15.91B
Beam Therapeutics Inc (BEAM) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
RJF (RJF) common stock.
Latest reported BEAM revenue for 2026-06-30 was $32.2M. Net income was -$217.0M. Revenue was up 1.5% from 2026-03-31 to 2026-06-30. BEAM currently screens at market cap $2.01B.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
BEAM currently screens at market cap $2.01B. RJF currently screens at market cap $0.
Not investment advice. Open the BEAM and RJF stock pages for the full models.
Not investment advice.